Sapna Patel: An important pathway in cancer signaling, including melanoma
The Video Journal of Oncology (VJOncology) shared on LinkedIn:
“New from ASCO2024: Phase I trial of SX-682, a CXCR1/2 inhibitor, in metastatic melanoma.
Sapna Patel, BA, MD, The University of Texas MD Anderson Cancer Center, remarks on a Phase I trial (NCT03161431) examining SX-682, a CXCR1/2 inhibitor, in combination with pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1 therapy.
Patients received increasing doses of SX-682, with primary endpoints focusing on safety and tolerability, and secondary endpoints including objective response rate (ORR) and overall survival (OS).
The results indicated a tolerable safety profile and encouraging clinical activity, with a notably longer median OS in this cohort. Learn more.”
Sapna Patel,
“This is an important pathway in cancer signaling, including melanoma.
Targeting CXCR1/2 signaling is not new, but this *new* small molecule inhibitor managed to generate responses in PD-1 refractory disease, including those whose melanoma had previously responded to immune checkpoint blockade.”
Source: Video Journal of Oncology (VJOncology)/LinkedIn and Sapna Patel/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023